Rob King joins FHI Clinical as Chief Operating Officer

December 20, 2019

FHI Clinical is pleased to announce that Rob King has joined the company as Chief Operating Officer. With more than 25 years in the clinical research industry, King has extensive experience in global clinical operations and executive leadership with a professional and academic focus in quality management and compliance. King has contributed to consistent double-digit growth at his last four organizations, and he is experienced in leading the acquisition and integration of global CRO and biotech companies.

Prior to joining FHI Clinical, King held the position of COO at Asklepios Biopharmacetical, Inc (AskBio), a gene therapy biotech. While there, he oversaw corporate growth, fundraising, integrations and facility expansion to allow for development of six adeno-associated virus (AAV) investigational products.

King also held the position of COO at Novella Clinical (now IQVIA Biotech), an oncology and medical device-focused global CRO. At Novella, he was responsible for global operations and client delivery across 1,500 staff and 52 countries. Prior to joining Novella, King was COO at Health Decisions, a CRO focused on women’s health. At Health Decisions, he oversaw global operations and served as project director for the clinical and statistical coordinating center for the National Institutes of Health-sponsored Contraceptive Clinical Network.

King served for seven years as an Adjunct Professor at Campbell University lecturing in clinical research, and he continues to serve on the Durham Technical Community College Clinical Trials Research Advisory Committee.

King holds a bachelor’s degree in psychology from the University of North Carolina at Wilmington and is certified in nonprofit management from Duke University.

news archive

Share this post